Condition: Acute Lymphocytic Leukemia · Sponsor: Chinese PLA General Hospital
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double gene deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL) subjects from the ATHENA trial (NCT06014073). Unexpectedly, expansion of the initial residual CD3-positive CAR T from products were measured in patients' peripheral blood (PB) without exception. Accompanying with host immune reconstitution and appearance of the detectable B cells, the CD3-positive allogenic CAR T cells exhibited a compelling amplification advantage over CD3-negative CAR T cells. The amplification of CD3-positive CAR T cell population dynamically suppressed host B cell recovery, and presumably surveilled the recurrence or progression of tumors, but did not induce typical Graft-versus-host-disease (GvHD). Additionally, a series of in vitro experiments illustrated that the human leukocyte antigen (HLA)-mismatched fratricide between host T cells and TCR-reserved Power3 (SPPL3)-deleted allogenic CAR T cells was markedly slashed, which in combination with investigators' observed clinical safety data supported the notion that only genomic deletion of Power3 (SPPL3) gene in allo-CAR T cells is sufficient to overcome GvHD and host T cell-mediated rejection response. In this study, investigators will disable the Power3 (SPPL3) gene of T cells from healthy donors to prepare CAR T cells (purified CAR-positive T cells \> 90%). This approach harnesse…
This description comes directly from the study's public registry record.
Weidong Han, Ph.D. · +86-010-55499341 · hanwdrsw@sina.com
Always discuss trial participation with your own doctor first.
| Biotherapeutic Department of Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Department of Hematology, Chinese PLA General Hospital | Beijing, China | Recruiting |
| Department of Hematology, Peking Union Medical College Hospital | Beijing, China | Not Yet Recruiting |
| Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College | Changzhi, China | Recruiting |
| Department of Hematology, Tianjin First Central Hospital | Tianjin, China | Recruiting |
| Immune Cell Therapy Center, Blood Disease Hospital, Chinese Academy of Medical Sciences | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06481735